Morgan Stanley Citius Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Citius Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 191,667 shares of CTXR stock, worth $101,583. This represents 0.0% of its overall portfolio holdings.

Number of Shares

191,667

Previous 243,959 21.43%

Holding current value

$101,583

Previous $185,000 7.03%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.6 - $0.9 $31,375 - $47,062	-52,292 Reduced 21.43%	191,667 $172,000
Q4 2023 Feb 13, 2024	BUY	$0.65 - $0.86 $109,162 - $144,430	167,943 Added 220.93%	243,959 $185,000
Q3 2023 Nov 15, 2023	SELL	$0.65 - $1.25 $18,203 - $35,006	-28,005 Reduced 26.92%	76,016 $51,000
Q2 2023 Aug 14, 2023	SELL	$1.08 - $1.65 $35,065 - $53,572	-32,468 Reduced 23.79%	104,021 $124,000
Q1 2023 May 15, 2023	BUY	$0.78 - $1.42 $19,589 - $35,663	25,115 Added 22.55%	136,489 $159,000

Q4 2022 Feb 14, 2023	SELL	$0.79 - $1.23 $29,337 - $45,677	-37,136 Reduced 25.01%	111,374 $87,000
Q3 2022 Nov 14, 2022	SELL	$0.14 - $1.33 $8,293 - $78,790	-59,241 Reduced 28.52%	148,510 $179,000
Q2 2022 Oct 27, 2022	BUY	$0.88 - $1.87 $142,154 - $302,077	161,539 Added 349.56%	207,751 $191,000
Q2 2022 Aug 15, 2022	BUY	$0.88 - $1.87 $142,154 - $302,077	161,539 Added 349.56%	207,751 $191,000
Q1 2022 Oct 27, 2022	SELL	$1.38 - $1.89 $222,923 - $305,308	-161,539 Reduced 77.76%	46,212 $83,000
Q1 2022 May 13, 2022	BUY	$1.38 - $1.89 $7,918 - $10,844	5,738 Added 14.18%	46,212 $83,000
Q4 2021 Feb 14, 2022	BUY	$1.51 - $2.2 $42,394 - $61,767	28,076 Added 226.46%	40,474 $61,000
Q3 2021 Nov 15, 2021	BUY	$1.74 - $2.6 $21,572 - $32,234	12,398 New	12,398 $25,000

Others Institutions Holding CTXR

# of Institutions

Shares Held

26.8M

Call Options Held

Put Options Held

View Full List

About Citius Pharmaceuticals, Inc.

Ticker CTXR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 146,130,000
Market Cap $77.4M
Description
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...

More about CTXR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account